지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한외과학회 Annals of Surgical Treatment and Research Annals of Surgical Treatment and Research Vol.103 No.5
- 발행연도
- 2022.11
- 수록면
- 271 - 279 (9page)
이용수
초록· 키워드
오류제보하기
Purpose: Although protein-induced vitamin K absence or antagonist II (PIVKA-II) has been used as a diagnostic tool for hepatocellular carcinoma (HCC), its prognostic value remains unclear.
Methods: This was a nationwide multicenter study using the database of the Korean Liver Cancer Association. Patients with hepatitis B-related HCC who underwent liver resection as the first treatment after initial diagnosis (2008–2014) were selected randomly. Propensity score matching (1:1) was performed for comparative analysis between those with low and high preoperative PIVKA-II. Univariable and multivariable Cox proportional-hazards regression were used to identify prognostic factors for HCC-specific survival.
Results: Among 6,770 patients, 956 patients were included in this study. After propensity score matching, the 2 groups (n = 245, each) were well balanced. The HCC-specific 5-year survival rate was 80.9% in the low PIVKA-II group and 78.7% in the high PIVKA-II group (P = 0.605). In univariable analysis, high PIVKA-II (>106.0 mAU/mL) was not a significant predictor for worse HCC-specific survival (hazard ratio [HR], 1.183; 95% confidence interval [CI], 0.76–1.85; P = 0.461). In multivariable analysis, hyponatremia of <135 mEq/L (HR, 4.855; 95% CI, 1.67–14.12; P = 0.004), preoperative ascites (HR, 4.072; 95% CI, 1.59–10.43; P = 0.003), microvascular invasion (HR, 3.112; 95% CI, 1.69–5.74; P < 0.001), and largest tumor size of ≥5.0 cm (HR, 2.665; 95% CI, 1.65–4.31; P < 0.001), but not preoperative high PIVKA-II, were independent predictors for worse HCCspecific survival.
Conclusion: Preoperative PIVKA-II is not an independent prognostic factor for HCC-specific survival after liver resection for hepatitis B-related HCC.
Methods: This was a nationwide multicenter study using the database of the Korean Liver Cancer Association. Patients with hepatitis B-related HCC who underwent liver resection as the first treatment after initial diagnosis (2008–2014) were selected randomly. Propensity score matching (1:1) was performed for comparative analysis between those with low and high preoperative PIVKA-II. Univariable and multivariable Cox proportional-hazards regression were used to identify prognostic factors for HCC-specific survival.
Results: Among 6,770 patients, 956 patients were included in this study. After propensity score matching, the 2 groups (n = 245, each) were well balanced. The HCC-specific 5-year survival rate was 80.9% in the low PIVKA-II group and 78.7% in the high PIVKA-II group (P = 0.605). In univariable analysis, high PIVKA-II (>106.0 mAU/mL) was not a significant predictor for worse HCC-specific survival (hazard ratio [HR], 1.183; 95% confidence interval [CI], 0.76–1.85; P = 0.461). In multivariable analysis, hyponatremia of <135 mEq/L (HR, 4.855; 95% CI, 1.67–14.12; P = 0.004), preoperative ascites (HR, 4.072; 95% CI, 1.59–10.43; P = 0.003), microvascular invasion (HR, 3.112; 95% CI, 1.69–5.74; P < 0.001), and largest tumor size of ≥5.0 cm (HR, 2.665; 95% CI, 1.65–4.31; P < 0.001), but not preoperative high PIVKA-II, were independent predictors for worse HCCspecific survival.
Conclusion: Preoperative PIVKA-II is not an independent prognostic factor for HCC-specific survival after liver resection for hepatitis B-related HCC.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Prognostic Value of Preoperative Protein Induced Vitamin K Absence or Antagonist II after Hepatectomy for Hepatitis B Related Hepatocellular Carcinoma: Nationwide Multicenter Study
대한외과학회 학술대회 초록집
2021 .05
-
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
Clinical and Molecular Hepatology
2023 .04
-
The Influence of Alcoholic Liver Disease on Serum PIVKA-II Levels in Patients without Hepatocellular Carcinoma
Gut and Liver
2015 .01
-
Clinical significance of PIVKA-II levels after liver transplantation for hepatocellular carcinoma
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
Predictors of Micrometastases in Patients with Barcelona Clinic Liver Cancer Classification B Hepatocellular Carcinoma
Yonsei Medical Journal
2017 .07
-
Laparoscopic liver resection versus percutaneous radiofrequency ablation for single small hepatocellular carcinoma (≤ 3 cm): Optimal indication based on the tumor size and the level of PIVKA-II
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
Laparoscopic liver resection versus percutaneous radiofrequency ablation for single small hepatocellular carcinoma (≤3cm): Optimal indication based on the tumor size and the level of PIVKA-II
대한임상종양학회 학술대회지
2022 .02
-
The prognosis in cases of hepatocellular carcinoma after hepatectomy: young patients versus older patients
Annals of Hepato-Biliary-Pancreatic Surgery
2015 .11
-
간세포암의 진단과 치료에서 종양표지자의 역할
대한내과학회지
2020 .02
-
Prognostic value of preoperative protein induced vitamin K absence or antagonist II after hepatectomy for hepatitis B related hepatocellular carcinoma: Nationwide multicenter study
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Diagnostic performance of serum exosomal miRNA-720 in hepatocellular carcinoma
Journal of Liver Cancer
2022 .03
-
AFP, PIVKA-II, AFP-L3 alone and in combination for early detection of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter analysis
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B
Clinical and Molecular Hepatology
2019 .01
-
Advances in Management of Hepatocellular Carcinoma
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Posttransplant sequential adrenal and spine metastasis of hepatocellular carcinoma responsive to combined regorafenib and radiotherapy: a case report
Clinical Transplantation and Research
2023 .03
-
환자표본자료를 이용한 간세포암종 환자의 의료이용 특성 및 치료별 의료비용 분석
한국임상약학회지
2021 .01
-
Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
Gut and Liver
2021 .01
-
Liver Transplantation in Mixed Hepatocellular Carcinoma and Cholangiocarcinoma
Journal of Liver Cancer
2019 .01
-
High Prevalence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection in Thailand
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective
Clinical and Molecular Hepatology
2023 .04
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2023-514-000222063